BMC Cancer | |
Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases | |
Research Article | |
Yolanda Barbachano1  Katharina Wassilew2  Andrew G Nicholson2  Gihan Ratnayake3  Ian Chau3  Eliza A Hawkes3  David Cunningham3  Sheela Rao3  George Ladas4  | |
[1] Department of Clinical Research and Development, Royal Marsden Hospital, London and Surrey, UK;Department of Histopathology, Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Division, Imperial College, London, UK;Department of Medicine, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, Surrey, UK;Department of Surgery, Royal Brompton and Harefield NHS Foundation Trust, London, UK; | |
关键词: Colorectal cancer; lung resection; peri-operative chemotherapy; | |
DOI : 10.1186/1471-2407-12-326 | |
received in 2012-05-04, accepted in 2012-07-17, 发布年份 2012 | |
来源: Springer | |
【 摘 要 】
BackgroundSurgery is often advocated in patients with resectable pulmonary metastases from colorectal cancer (CRC). Our study aims to evaluate peri-operative chemotherapy in patients with metastastic CRC undergoing pulmonary metastasectomy.MethodsPatients treated for CRC who underwent pulmonary metastasectomy by a single surgeon were identified. Outcome measures included survival, peri-operative complications, radiological and histological evidence of chemotherapy-induced lung toxicities.ResultsBetween 1997 and 2009, 51 eligible patients were identified undergoing a total of 72 pulmonary resections. Thirty-eight patients received peri-operative chemotherapy, of whom 9 received an additional biological agent. Five-year overall survival rate was 72% in the whole cohort - 74% and 68% in those who received peri-operative chemotherapy (CS) and those who underwent surgery alone (S) respectively. Five-year relapse free survival rate was 31% in the whole cohort - 38% and ≤18% in CS and S groups respectively. Only 8% had disease progression during neoadjuvant chemotherapy. There were no post-operative deaths. Surgical complications occurred in only 4% of patients who received pre-operative chemotherapy. There was neither radiological nor histological evidence of lung toxicity in resected surgical specimens.ConclusionsPeri-operative chemotherapy can be safely delivered to CRC patients undergoing pulmonary metastasectomy. Survival in this selected group of patients was favourable.
【 授权许可】
Unknown
© Hawkes et al.; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202311104036835ZK.pdf | 490KB | download |
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]